UK Regulator OKs Gilead Sciences' HIV-1 Prevention Treatment

10:48 AM EST, 12/19/2025 (MT Newswires) -- The UK's Medicines and Healthcare products Regulatory Agency approved Gilead Sciences' (GIS.F) Yeytuo for preventing sexually transmitted HIV-1 infection in adolescents and adults, according to a Friday notice. The biopharmaceutical company's Yeytuo, or lenacapavir, is administered through a combination of tablets and injections. It prevents the HIV-1 virus from multiplying and spreading. The agency noted that Yeytuo is subject to additional monitoring to quickly identify any new safety information.